NCT05313074View on ClinicalTrials.gov

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

February 25, 2022

Study Completion Date

February 25, 2022

Conditions
COVID-19Cancer
Interventions
BIOLOGICAL

CoronaVac vaccine

An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.

Trial Locations (1)

10400

National Cancer Institute, Ratchathewi

All Listed Sponsors
collaborator

Mahidol University

OTHER

lead

National Cancer Institute, Thailand

OTHER_GOV

NCT05313074 - SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients | Biotech Hunter | Biotech Hunter